Praxis Precision Medicines

Q2 FY2026 EarningsQ2 FY2026 results significantly beat expectations on the bottom line, with a Diluted EPS loss of -$2.87 vs. -$3.66 expected, driven by lower-than-anticipated operating expenses and strong interest income. While revenue remains at zero as expected for this pre-commercial biotech, the cash runway was extended into 2028 following a successful $1.4B capital raise. Key regulatory milestones were achieved with successful FDA mid-cycle meetings for ulixacaltamide and relutrigine, both of which identified no major safety or efficacy concerns.